-
EP1793824
European procedure
Extract from the Register of European Patents
EP About this file: EP1793824
| EP1793824 - NEW PHARMACEUTICAL COMPOSITIONS COMPRISING 4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-3-FLUORO-PHENOXY)-PYRIDINE-2-CARBOXYLIC ACID FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS [Right-click to bookmark this link] | Status | Patent revoked Status updated on 19.01.2022 Database last updated on 20.12.2024 | |
| Former | The patent has been granted Status updated on 27.11.2017 | Most recent event Tooltip | 21.01.2022 | Revocation of patent | published on 23.02.2022 [2022/08] | Applicant(s) | For all designated states Bayer HealthCare LLC 100 Bayer Boulevard Whippany, NJ 07981-0915 / US | [2014/47] |
| Former [2010/27] | For all designated states Bayer HealthCare LLC 555 White Plains Road Tarrytown, NY 10591 / US | ||
| Former [2007/24] | For all designated states Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 / US | Inventor(s) | 01 /
DUMAS, Jacques 98 Farmview Road Bethany, CT 06524 / US | 02 /
EHRLICH, Paul Bockumer Straase 48 40489 Duesseldorf-Wittlaer / DE | 03 /
ZULEGER, Susanne Klosterstrasse 92 50931 Koeln / DE | [2007/24] | Representative(s) | Weickmann & Weickmann PartmbB Postfach 860 820 81635 München / DE | [N/P] |
| Former [2015/47] | BIP Patents, et al c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 10 40789 Monheim am Rhein / DE | ||
| Former [2013/29] | BIP Patents, et al Bayer Intellectual Property GmbH IPO-P-MON Creative Campus Monheim Alfred-Nobel-Straße 10 40789 Monheim / DE | ||
| Former [2010/27] | Köhler, Ferdinand, et al Bayer Healthcare AG Law & Patents Patents and Licensing Building Q 18 51368 Leverkusen / DE | ||
| Former [2007/24] | Albers, Markus Bayer HealthCare AG LP-PL, Q 18 51368 Leverkusen / DE | Application number, filing date | 05792486.2 | 29.08.2005 | [2007/24] | WO2005US30541 | Priority number, date | US20040604752P | 27.08.2004 Original published format: US 604752 P | [2007/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2006026500 | Date: | 09.03.2006 | Language: | EN | [2006/10] | Type: | A1 Application with search report | No.: | EP1793824 | Date: | 13.06.2007 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.03.2006 takes the place of the publication of the European patent application. | [2007/24] | Type: | B1 Patent specification | No.: | EP1793824 | Date: | 18.11.2015 | Language: | EN | [2015/47] | Search report(s) | International search report - published on: | EP | 09.03.2006 | Classification | IPC: | A61K31/44, A61K31/4415, A61K9/14, A61K9/16, A61K9/20, A61P35/00 | [2015/22] | CPC: |
A61K31/44 (EP,KR,NO,US);
A61K31/4415 (EP,US);
A61K9/0053 (US);
A61K9/14 (NO);
A61K9/146 (EP,US);
A61K9/16 (KR);
A61K9/1623 (US);
A61K9/1635 (EP,US);
A61K9/1652 (EP,US);
A61K9/2027 (EP,US);
A61K9/2054 (EP,US);
A61K9/48 (US);
|
| Former IPC [2007/24] | A61K31/44, A61K9/16, A61P35/00 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2015/47] |
| Former [2007/24] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | Extension states | BA | 27.03.2007 | HR | 27.03.2007 | MK | 27.03.2007 | YU | 27.03.2007 | Title | German: | NEUE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT 4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-3-FLUOR-PHENOXY)-PYRIDIN-2-CARBONSÄURE ZUR BEHANDLUNG VON HYPERPROLIFERATIVEN ERKRANKUNGEN | [2007/24] | English: | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING 4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-3-FLUORO-PHENOXY)-PYRIDINE-2-CARBOXYLIC ACID FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | [2007/24] | French: | COMPOSITIONS PHARMACEUTIQUES COMPORTANT DE L'ACIDE 4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-3-FLUORO-PHENOXY)-PYRIDINE-2-CARBOXYLIQUE POUR LE TRAITEMENT DE TROUBLES HYPERPROLIFERATIFS | [2007/24] | Entry into regional phase | 27.03.2007 | National basic fee paid | 27.03.2007 | Designation fee(s) paid | 27.03.2007 | Examination fee paid | Examination procedure | 27.06.2006 | Request for preliminary examination filed International Preliminary Examining Authority: US | 27.03.2007 | Examination requested [2007/24] | 14.01.2011 | Despatch of a communication from the examining division (Time limit: M06) | 20.07.2011 | Reply to a communication from the examining division | 14.12.2011 | Despatch of a communication from the examining division (Time limit: M06) | 19.06.2012 | Reply to a communication from the examining division | 02.11.2012 | Despatch of a communication from the examining division (Time limit: M04) | 11.01.2013 | Reply to a communication from the examining division | 25.03.2013 | Despatch of a communication from the examining division (Time limit: M02) | 23.04.2013 | Reply to a communication from the examining division | 20.02.2014 | Despatch of a communication from the examining division (Time limit: M06) | 20.08.2014 | Reply to a communication from the examining division | 26.05.2015 | Communication of intention to grant the patent | 08.06.2015 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 14.07.2015 | Communication of intention to grant the patent | 08.10.2015 | Fee for grant paid | 08.10.2015 | Fee for publishing/printing paid | 08.10.2015 | Receipt of the translation of the claim(s) | Divisional application(s) | EP13151040.6 / EP2589384 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 14.01.2011 | Opposition(s) | Opponent(s) | 01
17.08.2016
23.08.2016
ADMISSIBLE Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Strasse 4 80335 München / DE Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE | [2016/39] | deleted | Deletion: Legal effect of rejection of opposition [ N /P ] | 26.09.2016 | Invitation to proprietor to file observations on the notice of opposition | 16.01.2017 | Reply of patent proprietor to notice(s) of opposition | 20.10.2017 | Date of oral proceedings | 28.11.2017 | Despatch of minutes of oral proceedings | 28.11.2017 | Date of despatch of rejection of opposition | 07.09.2021 | Legal effect of revocation of patent [2022/08] | 17.12.2021 | Despatch of communication that the patent will be revoked | Appeal following opposition | 08.02.2018 | Appeal received No. T0377/18 | 06.04.2018 | Statement of grounds filed | 07.09.2021 | Result of appeal procedure: revocation of the patent | 17.12.2021 | Despatch of the decision of the Board of Appeal | 07.09.2021 | Date of oral proceedings | Fees paid | Renewal fee | 31.08.2007 | Renewal fee patent year 03 | 22.03.2008 | Renewal fee patent year 04 | 31.08.2009 | Renewal fee patent year 05 | 31.08.2010 | Renewal fee patent year 06 | 31.08.2011 | Renewal fee patent year 07 | 27.08.2012 | Renewal fee patent year 08 | 27.08.2013 | Renewal fee patent year 09 | 13.08.2014 | Renewal fee patent year 10 | 10.08.2015 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | deleted | [2016/27] |
| Former [2016/25] | LV | 18.11.2015 | Cited in | International search | [DY]WO0042012 (BAYER AG [US], et al) [DY] 1-35 * page 4, line 12-14; compound 49 in table 4 *; | [Y]WO0041698 (BAYER AG [US], et al) [Y] 1-35 * page 8, line 10 - page 11, line 6; compound 49 in table 4 *; | [Y]WO03068228 (BAYER AG [US], et al) [Y] 1-35 * page 4, line 1- page, line 21; compound 49 on page 57 *; | [PX]WO2005009961 (BAYER PHARMACEUTICALS CORP [US], et al) [PX] 1-35* examples 1-11 on pages 47-56 *; | [Y] - AHMAD TANYA ET AL, "Kinase inhibition with BAY 43-9006 in renal cell carcinoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 SEP 2004, Presentation at First International Conference on Innovations and Challenges in Renal Cancer, Cambridge, Massachusetts, (20040319), vol. 10, no. 18 Pt 2, ISSN 1078-0432, pages 6388S - 92S, XP002362669 [Y] 1-35 * formula and table on page 6389S * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-040028 | [A] - LEUNER C ET AL, "Improving drug solubility for oral delivery using solid dispersions", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, (20000703), vol. 50, no. 1, ISSN 0939-6411, pages 47 - 60, XP004257179 [A] 1-35 * the whole document * DOI: http://dx.doi.org/10.1016/S0939-6411(00)00076-X | Examination | - WILHELM SCOTT M ET AL, "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity", INTERNATIONAL JOURNAL OF CANCER, (201107), vol. 129, no. 1, ISSN 0020-7136(print), pages 245 - 255 | - WILHELM SCOTT ET AL, "Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.", NATURE REVIEWS. DRUG DISCOVERY OCT 2006 LNKD- PUBMED:17016424, (200610), vol. 5, no. 10, ISSN 1474-1776, pages 835 - 844 | - Bruno C Hancock ET AL, Pharmaceutical Research, (20000101), vol. 17, XP055102285 | other | - European Medicines Agency Science Medicines Health,, "Assessment report Stivarga International non-proprietary name: REGORAFENIB", Assessment report EMA/467788/2017, (20170704), pages 1 - 91, XP055714681 | Opposition | WO0042012 | EP1350792 | WO2005009961 | - Excerpt from the DrugBank, page 1 and 4, URL: http://www.drugbank.ca/drugs/DB08896 | - C. LEUNER et al., "Improving drug solubility for oral delivery using solid dispersions", Eur. J. Pharm. Biopharm., (20000000), vol. 50, pages 47 - 60, XP004257179 DOI: http://dx.doi.org/10.1016/S0939-6411(00)00076-X |